Castro-Lopes Alexandre, Correia Sofia, Leal Cátia, Resende Inês, Soares Pedro, Azevedo Ana, Paiva José-Artur
Faculty of Medicine of the University of Porto, 4200-319 Porto, Portugal.
EPIUnit, Public Health Institute of University of Porto, 4050-091 Porto, Portugal.
Antibiotics (Basel). 2021 Jun 25;10(7):778. doi: 10.3390/antibiotics10070778.
: The COVID-19 pandemic poses novel challenges in antimicrobial consumption metrics and stewardship strategies. COVID-19 patients became the major cause of hospital admission during the first wave of the pandemic, often leading to an antimicrobial prescription upon admission or treatment for superinfections. The aim of this study was to understand how antimicrobial consumption was impacted at the beginning of the pandemic in a tertiary care hospital, a reference center for COVID-19. : A retrospective before-and-after study was done. Descriptive statistics of discharges, patient-days, and antimicrobial use indicators (defined daily doses (DDD)/100 discharges, DDD/100 patient-days) for various groups were calculated for the first three months of the pandemic (March, April, and May 2020) as a quarterly value, and for each year in 2011-2019, and their annual percentage changes were used to estimate 95% confidence intervals. The indicators were compared to patient type (medical/surgical), type of admission (urgent/elective), and age groups using Spearman's correlation coefficient. : Statistically significant increases occurred in 2020 for total antibacterials, macrolides, cephalosporins, amoxicillin/clavulanic acid, carbapenems, meropenem, and third-generation cephalosporins, while a reduction was seen in cefazolin/cefoxitin. A correlation was found between antibacterial consumption and patient or admission type. In 2020, unlike in pre-pandemic years, there was a different impact in DDD/100 discharges and DDD/100 patient-days due to increased lengths-of-stay and longer antimicrobial therapy. : The COVID-19 pandemic led to an increase in antimicrobial consumption with a different impact in DDD/100 discharges and DDD/100 patient-days. This highlights the need to use both indicators simultaneously to better understand the causes of antimicrobial consumption variation and improve the design of effective antimicrobial stewardship interventions.
新型冠状病毒肺炎大流行在抗菌药物使用指标和管理策略方面带来了新的挑战。在大流行的第一波期间,新型冠状病毒肺炎患者成为住院的主要原因,入院时或治疗继发感染时常常会开具抗菌药物处方。本研究的目的是了解在一家三级护理医院(新型冠状病毒肺炎参考中心)大流行开始时抗菌药物的使用受到了怎样的影响。
开展了一项回顾性前后对照研究。计算了大流行前三个月(2020年3月、4月和5月)各群体出院人数、患者住院天数和抗菌药物使用指标(限定日剂量(DDD)/100例出院、DDD/100患者住院天数)的季度值,并计算了2011 - 2019年各年的指标,用其年度百分比变化来估计95%置信区间。使用Spearman相关系数将这些指标与患者类型(内科/外科)、入院类型(急诊/择期)和年龄组进行比较。
2020年,总抗菌药物、大环内酯类、头孢菌素类、阿莫西林/克拉维酸、碳青霉烯类、美罗培南和第三代头孢菌素类的使用量出现了统计学上的显著增加,而头孢唑林/头孢西丁的使用量有所减少。发现抗菌药物使用与患者或入院类型之间存在相关性。2020年,与大流行前的年份不同,由于住院时间延长和抗菌治疗时间变长,DDD/100例出院和DDD/100患者住院天数受到了不同的影响。
新型冠状病毒肺炎大流行导致抗菌药物使用量增加,且对DDD/100例出院和DDD/100患者住院天数产生了不同的影响。这凸显了同时使用这两个指标以更好地理解抗菌药物使用变化原因并改进有效抗菌药物管理干预措施设计的必要性。